Avara Pharmaceutical Services Inc. acquires major sterile manufacturing facility and development center
August 31, 2018
On August 31, 2018, Avara Pharmaceutical Services Inc. completed the acquisition of Novartis Technical Operations’ sterile manufacturing facility from Sandoz Canada Inc. Avara also acquired the Sandoz Development Center located on the same site in Boucherville, Quebec.
The acquisition gives Avara access to the largest sterile manufacturing facility for injectable medicines in Canada.
Avara is a global pharmaceutical services company based in Norwalk, Connecticut. It has manufacturing facilities in North America and Europe and supplies products to all major markets around the world.
Sandoz is a global leader in generic pharmaceuticals and biosimilars, and is a subsidiary of Novartis AG.
McCarthy Tétrault LLP advised Avara with a team led by Hadrien Montagne that included Isabelle Nazon (Corporate), Dominic Thérien and Stéphanie St-Jean (Competition), Lisa Melanson, Benjamin Lai and Marissa Caldwell (Intellectual Property and Regulatory), Sébastien Thomas (Real Property), Cindy Vaillancourt (Environmental), Fred Purkey, Nicolas Désy and Anthony Sylvain (Tax), and Diana Theophilopoulos (Labour & Employment).